Pura Vida Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Pura Vida Investments’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,000	Closed	-$1.29M	–	256
2022 Q3	$1.4M	Buy	+20,000	New	+$1.48M	0.08%	148
2022 Q1	–	Sell	-4,872	Closed	-$715K	–	301
2021 Q4	$715K	Sell	4,872 -10,128	-68%	-$1.57M	0.03%	196
2021 Q3	$2.65M	Sell	15,000 -24,522	-62%	-$3.95M	0.08%	178
2021 Q2	$6.38M	Buy	39,522 +9,280	+31%	+$1.49M	0.2%	100
2021 Q1	$5.18M	Buy	30,242 +20,242	+202%	+$4.01M	0.15%	118
2020 Q4	$2.2M	Buy	+10,000	New	+$2.16M	0.08%	142

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pura Vida Investments's MRTX Position: Q4 2022 in Review

Pura Vida Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 20,000 shares — an estimated $1.29M sold.

Pura Vida Investments first reported a position in MRTX in Q4 2020 and held it in 6 quarters. The position peaked at $6.38M in Q2 2021. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

Pura Vida Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Pura Vida Investments sold 20,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1.29M.
Pura Vida Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Pura Vida Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $6.38M in Q2 2021.
233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.